Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma

NCT00699374 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00699374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00699374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2008
Completion date
December 31, 2011
Enrollment
1,075 (actual)
Sites
171

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular